Connect
← Return to Just approved: Evusheld for the pre-exposure prevention of COVID-19
Discussion
Just approved: Evusheld for the pre-exposure prevention of COVID-19
Transplants | Last Active: Aug 19, 2022 | Replies (173)Comment receiving replies
My concern is whether these monoclonal antibodies against the spike protein will worsen my existing autoimmune reaction caused by the Pfizer vaccine. Published research indicates I likely still have spike protein, which was produced by the vaccine, in my white blood cells. That spike protein is the target for the monoclonal antibodies in Evusheld. I talked to my rheumatologist about this issue and she said no one knows how I would react to the Evusheld product (another Emergency Use Authorization). A note of caution for the thousands of us who experienced severe adverse reactions to the Covid vaccines.
Replies to "My concern is whether these monoclonal antibodies against the spike protein will worsen my existing autoimmune..."
I have CIDP. I got the two Evusheld shots this Tuesday. It's Friday and so far so good.. The Pfizer vaccine caused a relapse from being mobile on foot to walker, cane and wheelchair. I'm on IVIG infusions once a week.
Connect
@pacer3702, I have autoimmune disease caused peripheral neuropathy, which increased after receiving the Pfizer vaccinations. Unfortunately, I caught Covid last month. I’m a liver transplant recipient, as such I was becoming quite ill. I was fortunate to receive monoclonal antibody treatment. I had a more severe reaction to the treatment however, including increased numbness and pain in my feet and legs, and new numbness in my face.